The Role of α5 GABAA Receptor Agonists in the Treatment of Cognitive Deficits in Schizophrenia
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Currently available pharmacotherapies for the treatment of schizophrenia are ineffective in restoring the disrupted cognitive function associated with this disorder. As such, there is a continued search for more viable novel drug targets. Engaging in cognitive behaviors is associated with distinct coordinated oscillatory activity across brain regions, in particular the hippocampus and prefrontal cortex. In schizophrenia patients, pathological alterations in the functionality of GABAergic interneurons in the PFC and HPC responsible for generating network oscillations are thought to contribute to impaired cognition. Destabilized GABAergic interneuron activity in the HPC is further associated with aberrant increases in HPC output and enhanced dopamine neuron activity. Consequently, drugs directed at restoring HPC function could impact both oscillatory activity along with dopamine tone. There is compelling evidence from animal models of schizophrenia that allosteric modulation of the α5 subunit of the GABAA receptor is a viable means of resolving aberrant dopamine system activity through indirect alteration of HPC output. Consequently, these compounds are promising for their potential in also ameliorating cognitive deficits attributed to dysfunction in HPC network activity. Keywords: α5GABAA receptors, schizophrenia, positive allosteric modulator, hippocampus, dopamine, ventral tegmental area.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neurophysiological investigation of the basis of the fMRI signal
Logothetis, N. K., Pauls, J., Augath, M., Trinath, T., & Oeltermann, A. (2001) · Nature · doi:10.1038/35084005 · Cited by 6,551 · cited 1×
“The diminished evoked gamma is proposed to be more relevant, since it would correlate with decreased metabolic responses to evoking stimuli [93] and hence the diminished accuracy in processing of sensory information.”
BackgroundParvalbumin neurons and gamma rhythms enhance cortical circuit performance
Sohal, V. S., Zhang, F., Yizhar, O., & Deisseroth, K. (2009) · Nature · doi:10.1038/nature07991 · Cited by 2,606 · cited 2×
“In corroboration, optogenetic inhibition of PV-expressing interneurons suppresses cortical gamma oscillations [38].”
BackgroundDriving fast-spiking cells induces gamma rhythm and controls sensory responses
Cardin, J. A., Carlén, M., Meletis, K., Knoblich, U., Zhang, F., Deisseroth, K., Tsai, L.-H., & Moore, C. I. (2009) · Nature · doi:10.1038/nature08002 · Cited by 2,603
Nelson, P. T., Alafuzoff, I., Bigio, E. H., Bouras, C., Braak, H., Cairns, N. J., Castellani, R. J., Crain, B. J., Davies, P., Tredici, K. D., et al. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31825018f7 · Cited by 2,050 · cited 1×
“In Alzheimer’s disease, a progressive loss of pyramidal projection neurons precedes and parallels the slow deterioration in cognitive function seen in this disorder, with the end result being massive cortical degeneration [45, 46].”
BackgroundAntipsychotic drug doses and neuroleptic/dopamine receptors
SEEMAN, P., LEE, T., CHAU-WONG, M., & WONG, K. (1976) · Nature · doi:10.1038/261717a0 · Cited by 1,622
Whittington, M. A., Traub, R. D., & Jefferys, J. G. R. (1995) · Nature · doi:10.1038/373612a0 · Cited by 1,613
Gamma (40-100 Hz) oscillation in the hippocampus of the behaving rat
Bragin, A., Jando, G., Nadasdy, Z., Hetke, J., Wise, K., & Buzsaki, G. (1995) · The Journal of Neuroscience · doi:10.1523/jneurosci.15-01-00047.1995 · Cited by 1,527
Storage of 7 +/- 2 short-term memories in oscillatory subcycles
Lisman, J. E., & Idiart, M. A. P. (1995) · Science · doi:10.1126/science.7878473 · Cited by 1,471
Which GABAA-receptor subtypes really occur in the brain?
McKernan, R. M., & Whiting, P. J. (1996) · Trends in Neurosciences · doi:10.1016/s0166-2236(96)80023-3 · Cited by 1,222
Neurocognition in first-episode schizophrenia: a meta-analytic review.
Mesholam-Gately, R. I., Giuliano, A. J., Goff, K. P., Faraone, S. V., & Seidman, L. J. (2009) · Neuropsychology · doi:10.1037/a0014708 · Cited by 1,130
Cited by
The Benzodiazepine Binding Sites of GABAA Receptors
Sigel, E., & Ernst, M. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.03.006 · Cited by 287
New Targets for Schizophrenia Treatment beyond the Dopamine Hypothesis
Yang, A., & Tsai, S.-J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081689 · Cited by 282
The neurobiology and treatment of first-episode schizophrenia
Kahn, R. S., & Sommer, I. E. (2015) · Molecular Psychiatry · doi:10.1038/mp.2014.66 · Cited by 219
Nimgampalle, M., Chakravarthy, H., Sharma, S., Shree, S., Bhat, A. R., Pradeepkiran, J. A., & Devanathan, V. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101994 · Cited by 207
Early interventions in risk groups for schizophrenia: what are we waiting for?
Sommer, I. E., Bearden, C. E., van Dellen, E., Breetvelt, E. J., Duijff, S. N., Maijer, K., van Amelsvoort, T., de Haan, L., Gur, R. E., Arango, C., et al. (2016) · npj Schizophrenia · doi:10.1038/npjschz.2016.3 · Cited by 140
Metadata
- Authors
- Gill, K., & Grace, A.
- Venue
- Current Pharmaceutical Design
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2014-08-31
- Volume
- 20
- Issue
- 31
- Pages
- 5069-5076
- ISSN
- 1381-6128 (ISSN-L)
- OpenAlex
- W1141854087
- Cited by
- 60
- References
- 38
- FWCI
- 3.82
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Role of α5 GABAA Receptor Agonists in the Treatment of Cognitive Deficits in Schizophrenia. https://app.cochat.ai/papers/10.2174/1381612819666131216114612
- The paper
- Gill, K., & Grace, A. (2014). The Role of α5 GABAA Receptor Agonists in the Treatment of Cognitive Deficits in Schizophrenia. Current Pharmaceutical Design. https://doi.org/10.2174/1381612819666131216114612
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.